Why India Needs a Differentiated Healthcare Margin and Pricing Strategy

India's maximum retail price system in healthcare often conceals supply chain margins and fails to reflect a product's actual clinical innovation value.

Trade-margin rationalisation by the National Pharmaceutical Pricing Authority previously demonstrated that regulated markups can reduce patient financial burdens.

Experts recommend establishing an independent panel to evaluate treatments based on clinical effectiveness, research risks, and overall health-system costs.